National Human Genome Research Institute; Notice of Closed Meetings, 7896-7897 [07-755]

Download as PDF 7896 Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices rmajette on PROD1PC67 with NOTICES non-endocrine tumors and malignancies. The inventor is continuing work on the development and functional characterization of the PDE11A and its variants in relation to iMAD and other tumors and malignancies of the endocrine system. Competitive Advantage of Our Technology Cushing Syndrome occurs in 5 to 10 per 15 million every year and 27,000 new cases of endocrine tumors are diagnosed every year. Our technology identifies a functional role of PDE11A in a new form of Cushing Syndrome and its possible role in endocrine tumors and/or other cancers. PDE inhibitors have been successfully used in the treatment of erectile dysfunction. Currently, there are three products in the market, which inhibit the different forms of PDEs for the treatment of erectile dysfunction: Sildeafil (Viagra), Vardenafil (Levitra) and Tadalafil (Cialis) manufactured by Pfizer, GlaxoSmithkline/Bayer/ScheringPlough and Lily Icos respectively. Among the marketed PDE inhibitors, Cialis targets PDE11A and PDE5A. Most interestingly, Cialis has no known effects on the adrenal gland and endocrine system and no PDE gene has ever been reported to be associated with endocrine or other human tumor development. Our invention of the variants of PDE11A genes and subsequent new protein PDE11A4 from one of the genetic variants have opened up the possibility of the development of new drugs for iMAD, adrenal hyperplasia and other endocrine tumors and malignancies targeting these proteins. The three marketed PDE inhibitors mentioned above have exceeded individual worldwide sales figures of 1 billion dollars each in 2007 and have been projected to grow steadily in the next few years. Additionally, the endocrine drug market has been projected to grow to more than 40 billion dollars in the next 5 years. New PDE inhibitors and the ones in the market are all in clinical trials for several diseases such as erectile dysfunction, neurological diseases and cardiovascular diseases. Our technology suggests that drugs that modulate PDE function can be used in treating iMAD, a rare genetic form of Cushing Syndrome with fatal implications in children. The new PDE11A gene variants that have been identified have diagnostic and therapeutic implications. PCR-based diagnostic tools can be developed to diagnose iMAD and novel antagonists VerDate Aug<31>2005 15:09 Feb 20, 2007 Jkt 211001 targeting these PDE11A variants can be identified and developed as drugs. DEPARTMENT OF HEALTH AND HUMAN SERVICES Patent Estate National Institutes of Health This technology consists of U.S. Provisional Applications Serial No. 60/ 761,446 entitled ‘‘PDE11A mutations in Adrenal Diseases’’ filed January 24, 2007. A PCT application has also been filed. National Heart, Lung, and Blood Institute; Notice of Closed Meeting Next Step: Teleconference There will be a teleconference where the principal investigator will explain this technology. Licensing and collaborative research opportunities will also be discussed. If you are interested in participating in this teleconference please call or e-mail Mojdeh Bahar; (301) 435–2950; baharm@mail.nih.gov. OTT will then e-mail you the date, time and number for the teleconference. Dated: February 13, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–2884 Filed 2–20–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Amended Notice of Meeting Notice is hereby given of a change and additional information for the meeting of the Advisory Committee to the Director, NIH, February 21, 2007, 2:30 to 4 p.m., National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 (Telephone Conference Call) which was published in the Federal Register on February 8, 2007, 72 FR 5982. The meeting will be held from 2:30 p.m. to 4:30 p.m. Also, individuals interested in attending the meeting must contact Dr. Penny W. Burgoon for telephone number and pass code. The meeting is open to the public. Dated: February 9, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–763 Filed 2–20–07; 8:45 am] BILLING CODE 4140–01–M PO 00000 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Research Demonstration and Dissemination Projects (R18). Date: March 6, 2007. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Patricia A. Haggerty, PhD, Scientific Review Administrator, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7194, Bethesda, MD 20892–7924, 301–435– 0288, haggertp@nhibi.nih.gob. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: February 9, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–761 Filed 2–20–07; 8:45 am] BILLING CODE 4140–07–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\21FEN1.SGM 21FEN1 Federal Register / Vol. 72, No. 34 / Wednesday, February 21, 2007 / Notices amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Human Genome Research Institute Special Emphasis Panel, MOUSE Repository RFA. Date: March 8, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Lombardy, 2019 Pennsylvania Ave., NW., Washington, DC 20006. Contact Person: Ken D. Nakamura, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301–402–0838. Name of Committee: National Human Genome Research Institute Special Emphasis Panel, Sequencing Technology RFA. Date: March 15–16, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Rouge, 1315 16th Street, NW., Washington, DC 20036. Contact Person: Ken D. Nakamura, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301–402–0838. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: February 13, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–755 Filed 2–20–07; 8:45 am] National Institute of Child Health and Human Development; Notice of Closed Meeting rmajette on PROD1PC67 with NOTICES BILLING CODE 4140–01–M National Institutes of Child Health and Human Development; Notice of Closed Meetings National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the Jkt 211001 Dated: February 12, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–751 Filed 2–20–07; 8:45 am] National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES 15:09 Feb 20, 2007 Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Maintenance and Operation of a Chemical Synthesis Facility. Date: February 27, 2007. Time: 12 p.m. to 1:30 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Hameed Khan, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, (301) 435–6902, khanh@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–M VerDate Aug<31>2005 provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 7897 applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Nutrient Restriction: Placental and Fetal Brain and Renal Outcomes and Mechanisms. Date: February 21, 2007. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Blvd., 5B01, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gopal M. Bhatnagar, PhD., Scientific Review Administrator, National Institute of Child Health and Human Development, National Institutes of Health, 6100 Bldg., Rm. 5B01, Rockville, MD 20852, (301) 435–6889, bhatnagg@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Child Health and Human Development Initial Review Group, Developmental Biology Subcommittee. Date: February 26–27, 2007. Time: 8 a.m. to 5 pm. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202. Contact Person: Norman Chang, PhD., Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, (301) 496–1485, changn@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Child Health and Human Development Initial Review Group; Biobehavioral and Behavioral Sciences Subcommittee. Date: February 27–28, 2007. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Marriott at Metro Center, 775 12th Street, NW., Washington, DC 20005. Contact Person: Marita R. Hopmann, PhD., Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01, Bethesda, MD 20892, (301) 435–6911, hopmannm@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and E:\FR\FM\21FEN1.SGM 21FEN1

Agencies

[Federal Register Volume 72, Number 34 (Wednesday, February 21, 2007)]
[Notices]
[Pages 7896-7897]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-755]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Human Genome Research Institute; Notice of Closed 
Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as

[[Page 7897]]

amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Human Genome Research Institute 
Special Emphasis Panel, MOUSE Repository RFA.
    Date: March 8, 2007.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hotel Lombardy, 2019 Pennsylvania Ave., NW., Washington, 
DC 20006.
    Contact Person: Ken D. Nakamura, PhD, Scientific Review 
Administrator, Office of Scientific Review, National Human Genome 
Research Institute, National Institutes of Health, Bethesda, MD 
20892, 301-402-0838.

    Name of Committee: National Human Genome Research Institute 
Special Emphasis Panel, Sequencing Technology RFA.
    Date: March 15-16, 2007.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hotel Rouge, 1315 16th Street, NW., Washington, DC 20036.
    Contact Person: Ken D. Nakamura, PhD, Scientific Review 
Administrator, Office of Scientific Review, National Human Genome 
Research Institute, National Institutes of Health, Bethesda, MD 
20892, 301-402-0838.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human 
Genome Research, National Institutes of Health, HHS)

    Dated: February 13, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-755 Filed 2-20-07; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.